Literature DB >> 28889405

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

D J Lewis1,2, Y H Kim3, M Duvic2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28889405     DOI: 10.1111/bjd.15970

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  1 in total

1.  JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Authors:  Sara Yumeen; Fatima N Mirza; Julia M Lewis; Amber Loren O King; Sa Rang Kim; Kacie R Carlson; Sheila R Umlauf; Yulia V Surovtseva; Francine M Foss; Michael Girardi
Journal:  Blood Adv       Date:  2020-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.